Regeneron, Sanofi: Dupixent Meets Endpoints in Severe Asthma Attacks in Children
13 October 2020 - 9:37PM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Tuesday said a
pivotal phase 3 study of the eczema drug Dupixent met its primary
and all key secondary endpoints in children ages six to 11 years
old with uncontrolled moderate-to-severe asthma.
The companies said Dupixent added to standard of care
significantly reduced severe asthma attacks by up to 65% over one
year compared to a placebo, adding that significant and rapid
improvement in lung function was seen within two weeks and
sustained for up to 52 weeks.
Regeneron and Sanofi said they plan to file for U.S. and
European regulatory approval in the indication by the first quarter
of next year.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it
jointly in the U.S. with France's Sanofi under a 2007 collaboration
agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 13, 2020 06:22 ET (10:22 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024